Following its recent acquisition of Curetis, OpGen has also shifted its focus onto its Unyvero molecular diagnostics platform and bioinformatics operations.
The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.